Skip to main content
TipRanks
Go Ultimate75% OFF

JMS Co., Ltd. (7702) AI Stock Analysis

0 Followers
JP:7702

JMS Co., Ltd.

(TSE/TYO:7702)

Select Model
Rating:34Underperform
Price Target:JPY 393.00â–¼(-5.53% Downside)
Action:reiterated
Date:11/18/26

JMS Co. scores poorly, driven primarily by a multi-year deterioration in financial performance: evaporating profitability with a projected FY2026 net loss, declining revenue, margin compression, a ~51% rise in debt, and persistently negative free cash flow. Technicals reinforce the caution, with the stock trading below all major moving averages and a negative MACD indicating a bearish trend. Valuation offers little support — the negative P/E reflects losses, and while the ~4.0% dividend yield appears appealing, weak cash generation raises doubts about its sustainability. A low beta provides some defensiveness, but it does not offset the fundamental risks. Note that earnings call and corporate event data were unavailable and excluded from the scoring.

Positive Factors
Recurring Consumables DemandJMS combines equipment sales with recurring single-use consumables used in routine procedures. Once hospitals standardize on compatible products, repeat purchasing can support steadier demand and improve customer retention across infusion, transfusion, and dialysis workflows.
Negative Factors
Declining Revenue and LossesRevenue contraction combined with a ¥0.8B net loss signals weakened demand conversion and insufficient operating leverage. Continued top-line pressure could make fixed costs harder to absorb, limiting earnings recovery and reducing the resources available for investment over the next several quarters.

JMS Co., Ltd. (7702) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%JP:7702-0.90%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 10.20B
Dividend Yield
4.09%
Average Volume (3M)
37.66K
Price to Earnings (P/E)
-11.9
Beta (1Y)
0.57
Revenue Growth
-3.10%
EPS Growth
-645.12%
Country
Japan
Employees
4,887
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

JMS Co., Ltd. Business Overview & Revenue Model

Company Description

JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Ja...

How the Company Makes Money

JMS makes money primarily by selling medical devices and associated disposable consumables to healthcare providers and distributors. Its revenue model typically combines (1) sales of durable or semi-durable equipment (devices used in hospitals and cl...

JMS Co., Ltd. Financial Statement Overview

Summary

Financials are weak across all three statements. Profitability has collapsed — net income fell from ¥1.74B in FY2021 to ¥89M in FY2025, with a ¥784M net loss projected for FY2026 on a 4.7% revenue decline. Gross margins compressed to ~23.3% and EBIT margins to under 1%. The balance sheet shows debt rising ~51% to ¥28.0B while equity grew only modestly, lifting debt-to-equity to 0.67, though equity still covers roughly half of total assets. Cash flow is the weakest link: operating cash flow fell to ~¥1.6B, free cash flow has been negative in four of the last five periods, and debt coverage has dropped below 6%, suggesting capex is being debt-funded.

Income Statement

18Very Negative

Balance Sheet

35Negative

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue66.02B65.84B69.75B65.29B63.74B58.17B
Gross Profit15.75B15.36B15.93B14.09B14.60B14.27B
EBITDA4.50B4.22B4.79B4.08B4.38B4.59B
Net Income-855.00M-784.00M89.00M-36.00M281.00M826.00M
Balance Sheet
Total Assets82.92B83.07B81.43B84.71B74.41B71.97B
Cash, Cash Equivalents and Short-Term Investments7.48B7.72B5.51B10.31B6.33B6.81B
Total Debt25.55B28.01B24.55B26.92B19.75B18.71B
Total Liabilities41.01B41.27B40.50B43.96B35.70B34.87B
Stockholders Equity41.86B41.73B40.84B40.57B38.53B36.96B
Cash Flow
Free Cash Flow0-892.00M-1.42B498.00M-1.07B1.14B
Operating Cash Flow01.58B1.47B3.14B2.48B4.40B
Investing Cash Flow0-2.25B-3.14B-4.24B-3.69B-3.68B
Financing Cash Flow02.69B-3.19B4.78B525.00M-499.00M

JMS Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price416.00

Price Trends

50DMA440.64Negative
100DMA444.81Negative
200DMA434.03Negative

Market Momentum

MACD-5.83Positive
RSI37.22Neutral
STOCH12.94Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7702, the sentiment is Negative. The current price of 416.00 is below the 20-day moving average (MA) of 429.90, below the 50-day MA of 440.64, and below the 200-day MA of 434.03, indicating a bearish trend. The MACD of -5.83 indicates Positive momentum. The RSI at 37.22 is Neutral, neither overbought nor oversold. The STOCH value of 12.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7702.

JMS Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7702 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7747JP:774775OutperformJPY 1.15T32.4221.31%1.11%22.57%138.10%
JP:4543JP:454371OutperformJPY 3.85T33.077.14%1.30%14.97%-12.99%
JP:7733JP:773365NeutralJPY 2.04T21.7811.80%3.27%9.03%-2.99%
JP:8086JP:808652NeutralJPY 270.15B22.003.85%2.13%5.03%0.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:7702JP:770234UnderperformJPY 10.31B-11.93―4.09%-3.10%-645.12%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%JP:7702JP:4543JP:7747JP:8086JP:7733Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7702 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7702JMS Co., Ltd.416.002.960.72%
JP:4543Terumo2547.00123.525.10%
JP:7747Asahi Intecc Co 4348.001492.4752.27%
JP:8086Nipro Corporation1456.50-2.29-0.16%
JP:7733Olympus Corp1833.00-167.72-8.38%

JMS Co., Ltd. Corporate Events

JMS Sales Rise Slightly as Net Loss Widens

Nov 6, 2026

JMS Co., Ltd. reported consolidated sales of ¥32.391 billion for the six months ended September 2026, up 0.5% year on year, while operating profit improved to ¥9 million from a ¥19 million loss. However, ordinary loss widened to ¥145 million from ¥46...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026